The global allergy diagnostics and therapeutics market size was estimated at USD 34.42 billion in 2024 and is projected to reach USD 78.00 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. The market’s expansion is driven by several key factors, including the rising incidence of allergies, technological advancements, the launch of new products, and the high adoption of immunotherapy drugs.

According to the Global Allergy and Airways Patient Platform in November 2022, approximately 30-40% of people today suffer from one or more allergies, and the number of individuals affected by allergies has been increasing steadily over the past 20 years. Factors such as changing lifestyles and growing environmental pollution are contributing significantly to the rise in allergic conditions.

The development and introduction of therapeutically advanced drugs, particularly immunotherapy, are addressing unmet patient needs and are expected to boost market growth over the forecast period. For example, in February 2024, the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children aged 1 year or older. Xolair is designed to reduce allergic reactions (Type I), including lowering the risk of anaphylaxis that may occur due to accidental exposure to multiple foods. The drug is intended for repeated use to manage and prevent allergic reactions over time but is not approved for immediate emergency treatment of allergic reactions, including anaphylaxis.

Key Market Trends & Insights:

• The North American allergy diagnostics and therapeutics market emerged as the dominant regional market globally, capturing the largest revenue share of 36.53% in 2024. Within this region, the U.S. led the market, holding the largest revenue share in 2024, driven by a combination of high allergy prevalence, advanced healthcare infrastructure, and widespread adoption of innovative diagnostic and therapeutic solutions.

• When segmented by type, the therapeutics segment dominated the global market, reflecting strong demand for treatment options such as immunotherapy and other allergy-relief medications. Meanwhile, the diagnostics segment accounted for the largest revenue share of 81.46% in 2024, highlighting the critical role of allergy testing in identifying specific allergens and informing appropriate treatment strategies.

• By allergen type, the inhaled segment held the largest revenue share of 49.77% in 2024, indicating that respiratory allergens, including pollen, dust, and mold, are the most prevalent triggers and continue to be a primary focus for both diagnostics and therapeutic interventions.

• By test type, the in vivo test segment captured the largest revenue share of 51.92% in 2024, reflecting the widespread use of methods such as skin-prick tests and patch tests. These in vivo tests provide direct, reliable detection of allergic reactions, enabling healthcare providers to develop personalized and effective treatment plans for patients.

Order a free sample PDF of the Allergy Diagnostics And Therapeutics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 34.42 Billion

• 2033 Projected Market Size: USD 78.00 Billion

• CAGR (2025-2033): 9.7%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

The allergy diagnostics and therapeutics industry is characterized by a highly competitive landscape, where market players actively engage in a variety of strategic initiatives to strengthen their position. Companies focus on strategic collaborations with other organizations, healthcare providers, and research institutions to enhance their capabilities and expand market reach. They also invest in new product launches to introduce innovative diagnostic tools and therapeutic solutions that meet evolving patient needs.

In addition, firms pursue acquisitions to consolidate market share and access new technologies or geographic regions. Technological advancements play a critical role in driving growth, enabling the development of more precise, efficient, and patient-friendly diagnostic and treatment options. Furthermore, companies engage in regional expansion strategies, entering emerging markets or strengthening their presence in existing markets to capture a broader customer base and increase revenue.

Key Players

• R-Biopharm AG

• R-Biopharm AG

• DASIT Group SPA

• EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)

• AESKU.GROUP GmbH

• bioMérieux

• Siemens Healthcare GmbH

• Stallergenes Greer

• HYCOR Biomedical

• Minaris Medical America, Inc.

• Omega Diagnostics Group PLC

• Lincoln Diagnostics, Inc.

• HOB Biotech Group Corp., Ltd.

• Danaher

• Alcon

• AbbVie, Inc.

• Sanofi

• Allergy Therapeutics

• Pfizer, Inc.

• Teva Pharmaceutical Industries Ltd.

• GSK plc

• Sun Pharmaceutical Industries Ltd

• F. Hoffmann-La Roche Ltd.

• Merck & Co., Inc.

• Astellas Pharma Inc.

• Epigenomics AG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The allergy diagnostics and therapeutics market is poised for strong growth as the prevalence of allergic conditions continues to rise globally. Increasing awareness about allergy testing, advancements in diagnostic technologies, and the introduction of innovative therapies are driving market expansion. Demand is supported by the need for precise, early diagnosis and effective treatment strategies, while ongoing investment in research, strategic collaborations, and expansion of healthcare infrastructure are further reinforcing market momentum. Overall, the market outlook remains positive as allergy related healthcare continues to evolve and expand.